Research and Development Investment: Neurocrine Biosciences, Inc. vs Protagonist Therapeutics, Inc.

Biotech R&D: Neurocrine vs. Protagonist's Decade of Growth

__timestampNeurocrine Biosciences, Inc.Protagonist Therapeutics, Inc.
Wednesday, January 1, 2014464250007459000
Thursday, January 1, 20158149100011831000
Friday, January 1, 20169429100025705000
Sunday, January 1, 201712182700046181000
Monday, January 1, 201816052400059497000
Tuesday, January 1, 201920000000065003000
Wednesday, January 1, 202027500000074506000
Friday, January 1, 2021328100000126006000
Saturday, January 1, 2022463800000126215000
Sunday, January 1, 2023565000000120161000
Monday, January 1, 2024731100000
Loading chart...

Unleashing insights

A Decade of Innovation: R&D Investments in Biotech

Neurocrine Biosciences vs. Protagonist Therapeutics

In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Neurocrine Biosciences, Inc. and Protagonist Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D spending. From 2014 to 2023, Neurocrine Biosciences increased its R&D expenses by over 1,100%, peaking at $565 million in 2023. This robust growth underscores their commitment to pioneering treatments and therapies.

Conversely, Protagonist Therapeutics, while also increasing its R&D investments, saw a more modest growth of approximately 1,500%, reaching $120 million in 2023. This disparity highlights the varying scales and strategies within the biotech sector. As these companies continue to innovate, their R&D investments will play a crucial role in shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025